Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636106 | 0.87 | CYP3A4 (0.45) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL31470226 | 0.87 | CYP3A4 (0.45) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL20865561 | 0.87 | ALDH1A1 (0.56) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL12330707 | 0.87 | ALDH1A1 (0.55) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL8297312 | 0.86 | SMN1; SMN2 (0.63) | LMNAPOLBHPGDALDH1A1HDAC3 | |
| SCHEMBL25736547 | 0.86 | ALDH1A1 (0.44) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL29991534 | 0.85 | AAK1 (0.49) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL4568010 | 0.85 | LMNA (0.56) | LMNANPSR1POLBALDH1A1GAA | |
| SCHEMBL18511360 | 0.85 | LMNA (0.43) | NLRP3LMNANPSR1CYP1A2CYP2C19 | |
| SCHEMBL5732332 | 0.85 | HPGD (0.46) | NLRP3LMNANPSR1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022126095-A1 | CONSUMER PRODUCTS COMPRISING CROSS-LINKED CARBON NANOTUBE SENSORS AND SYSTEMS AND METHODS COMPRISING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022126094-A1 | CONSUMER PRODUCTS COMPRISING CROSS-LINKED CARBON NANOTUBE SENSORS AND SYSTEMS AND METHODS COMPRISING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220178896-A1 | CONSUMER PRODUCTS COMPRISING CROSS-LINKED CARBON NANOTUBE SENSORS AND SYSTEMS AND METHODS COMPRISING THE SAME | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | disclosed |
| US-9388166-B2 | 6-aminoindole derivatives as TRP channel antagonists | HOFFMAN-LA ROCHE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150218133-A1 | 6-AMINOINDOLE DERIVATIVES AS TRP CHANNEL ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| CN-1068588-C | 1H-indole-3-acetamide splA2 inhibitors | LILLY CO ELI (US) | 2001-07-18 | — | — | CN | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | NLRP3 1706/4885LMNA 4472/4885NPSR1 27/4885 |
| US-20150218133-A1 | 6-AMINOINDOLE DERIVATIVES AS TRP CHANNEL ANTAGONISTS | TRPC6, TRPC5, HTR6 | NLRP3 924/4885LMNA 3654/4885NPSR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.